KMDA Kamada Ltd.
Kamada Ltd. (KMDA) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.9% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Kamada Ltd.
Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops and produces specialty plasma-derived protein therapeutics. Its product candidates include Glassia and Inhaled Alpha-1 Antitrypsin for its deficiency.
Sector
Healthcare
Industry
Biotechnology